JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran
Shahriari-Ahmadi, Ali; Fahimi, Ali; Payandeh, Mehrdad; Sadeghi, Masoud;
  PDF(new window)
 Abstract
Background: The chemotherapeutic agent oxaliplatin can cause acute and chronic forms of peripheral neuropathy. The aim of this study was to evaluate the incidence of chronic neuropathy and its risk factors in colorectal cancer (CRC) patients treated with FOLFOX or XELOX regimens in the Oncology Ward of Hazrate-Rasoul Hospital in Tehran. Materials and Methods: A total of 130 patients with CRC were entered into our study, aged over 18 years, without history of receiving other neurotoxic agents or other predisposing factors such as diabetes or neurologic diseases and kidney and liver dysfunction. For the FOLFOX regimen, patients received oxaliplatin, 85mg/m2, every 2 weeks for 12 courses and with the XELOX regimen, oxaliplatin was , every 3 weeks for 8 courses. Based on Common Toxicity Criteria (CTC or NCI-CTC v.3), the patients were divided into 5 groups (grades) based on the severity of their symptoms. Results: Fifty-seven patients (43.8%) were male and 73(56.2%) female. Some 19 patients (14.7%) had BMI<20, 97(74.6%) were between 20-25 and 14 (10.8%) . In 105 patients (80.7%) neuropathy was found. There was significant correlation between BMI, hypomagnesaemia and especially, severity of anemia in patients with neuropathy compared to those without. Conclusions: Oxaliplatin regimens can induce chronic neuropathy in CRC patients, with anemia, high BMI and hypomagnesaemia as risk factors that can predispose to this kind of neurotoxicity.
 Keywords
Anemia;chronic neuropathy;colorectal cancer;oxaliplatin;
 Language
English
 Cited by
1.
Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk, Breast Cancer Research and Treatment, 2016, 159, 2, 327  crossref(new windwow)
2.
Fit for Chemo: Nerves May Thank You, Journal of the National Cancer Institute, 2017, 109, 2, djw208  crossref(new windwow)
3.
Chemotherapy-induced peripheral neuropathy: A current review, Annals of Neurology, 2017, 81, 6, 772  crossref(new windwow)
 References
1.
Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S (2013). Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol, 36, 331-7. crossref(new window)

2.
Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51. crossref(new window)

3.
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G(2012). Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol, 82, 51-77. crossref(new window)

4.
Argyriou AA, Polychronopoulos P, Iconomou G, et al (2007). Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol, 46, 1131-7. crossref(new window)

5.
Argyriou AA, Zolota V, Kyriakopoulou O, Kalofonos HP(2010). Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON, 15, 435-46.

6.
Azadeh S, Moghimi-Dehkordi B, Fatem SR, et al (2008). Colorectal cancer in Iran: an epidemiological study. Asian Pac J Cancer Prev, 9, 123-6.

7.
Baek KK, Lee J, Park SH, et al (2010). Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat, 42, 185-90. crossref(new window)

8.
Cassidy J, Clarke S, Diaz-Rubio E, et al (2011). XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cance, 105, 58-64. crossref(new window)

9.
Cassidy J, Tabernero J, Twelves C, et al (2004). XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 22, 2084-91. crossref(new window)

10.
Cersosimo RJ(2005). Oxaliplatin-associated neuropathy: a review. The Annals of Pharmacology, 39, 128-35.

11.
Chau I, Cunningham D(2006). Adjuvant therapy in colon cancer- -what, when and how? Ann Oncol, 17, 1347-59. crossref(new window)

12.
de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.

13.
Gamelin L, Boisdron-Celle M, Delva R, et al (2004). Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res, 10, 4055-61. crossref(new window)

14.
Gamelin E, Gamelin L, Bossi L, Quasthoff S(2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol, 29, 21-33. crossref(new window)

15.
Kalofonos HP, Aravantinos G, Kosmidis P, et al (2005). Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol, 16, 869-77. crossref(new window)

16.
Kono T, Satomi M, Asama T, et al (2010). Cetuximabinduced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. J Gastrointest Oncol, 1, 97-101.

17.
Meyerhardt JA, Tepper JE, Niedzwiecki D, et al (2004). Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol, 22, 648-57. crossref(new window)

18.
Park SB, Goldstein D, Lin CS, et al(2009). Acute abnormalities of sensory nerve function associated with oxaliplatininduced neurotoxicity. J Clin Oncol, 27, 1243-9. crossref(new window)

19.
Payandeh M, Sadeghi M, Sadeghi E, Gholami F (2015). Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. Am J Cancer Prev, 3, 19-22.

20.
Rothenberg ML, Cox JV, Butts C, et al (2008). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol, 19, 1720-6. crossref(new window)

21.
Saif MW, Wilson RH, Harold N, et al (2001). Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs, 12, 525-31. crossref(new window)

22.
Sittl R, Lampert A, Huth T, et al (2012). Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A, 109, 6704-9. crossref(new window)

23.
Stone WL, Krishnan K, Campbell SE, et al (2004). Tocopherols and the treatment of colon cancer. Ann NY Acad Sci, 1031, 223-33. crossref(new window)

24.
Storey DJ, Sakala M, McLean CM, et al (2010). Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol, 21, 1657-61. crossref(new window)

25.
Vincenzi B, Frezza AM, Schiavon G, et al (2013). Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer, 21, 1313-9. crossref(new window)